108 related articles for article (PubMed ID: 30660512)
1. Cardiovascular Risk and Cardiovascular Events in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors.
Assunção PM; Lana TP; Delamain MT; Duarte GO; Zulli R; Lorand-Metze I; de Souza CA; de Paula EV; Barbosa Pagnano KB
Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):162-166. PubMed ID: 30660512
[TBL] [Abstract][Full Text] [Related]
2. Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.
Molica M; Scalzulli E; Colafigli G; Fegatelli DA; Massaro F; Latagliata R; Foà R; Breccia M
Ann Hematol; 2018 Oct; 97(10):1803-1808. PubMed ID: 29806063
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors in Taiwan: a nationwide population-based study.
Yang YC; Huang RY; Tsai HJ; Li PC; Yang YH; Hsieh KP
Eur J Prev Cardiol; 2022 Jul; 29(9):1312-1321. PubMed ID: 34179961
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up.
Aghel N; Lipton JH; Atenafu EG; Kim DDH; Delgado DH
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):870-878.e1. PubMed ID: 28803825
[TBL] [Abstract][Full Text] [Related]
5. Incidence of cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors.
Casavecchia G; Spinosa G; De Gennaro L; Zicchino S; Gravina M; Magnesa M; Di Biase M; Brunetti ND
Acta Cardiol; 2022 Apr; 77(2):130-135. PubMed ID: 33685352
[TBL] [Abstract][Full Text] [Related]
6. [Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].
Rea D; Ame S; Charbonnier A; Coiteux V; Cony-Makhoul P; Escoffre-Barbe M; Etienne G; Gardembas M; Guerci-Bresler A; Legros L; Nicolini F; Tulliez M; Hermet E; Huguet F; Johnson-Ansah H; Lapusan S; Quittet P; Rousselot P; Mahon FX; Messas E
Bull Cancer; 2016 Feb; 103(2):180-9. PubMed ID: 26790711
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular events and atherogenic lipid profile in chronic myeloid leukemia patients treated with nilotinib versus imatinib.
Petrikova L; Slezakova K; Sninska Z; Harvanova L; Martisova M; Hatalova A; Mistrik M; Batorova A; Mladosievicova B
Bratisl Lek Listy; 2021; 122(8):531-537. PubMed ID: 34282617
[TBL] [Abstract][Full Text] [Related]
8. Association of Nilotinib With Cardiovascular Diseases in Patients With Chronic Myelogenous Leukemia: A National Population-Based Cohort Study.
Huang CE; Lee KD; Chang JJ; Tzeng HE; Huang SH; Yu LH; Chen MC
Oncologist; 2024 Jan; 29(1):e81-e89. PubMed ID: 37561957
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease.
Leong D; Aghel N; Hillis C; Siegal D; Karampatos S; Rangarajan S; Pond G; Seow H
Heart; 2021 Apr; 107(8):667-673. PubMed ID: 33419879
[TBL] [Abstract][Full Text] [Related]
10. Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention.
Caocci G; Mulas O; Bonifacio M; Abruzzese E; Galimberti S; Orlandi EM; Iurlo A; Annunziata M; Luciano L; Castagnetti F; Gozzini A; Stagno F; Binotto G; Pregno P; Albano F; Martino B; Fozza C; Scaffidi L; Trawinska MM; Baratè C; Elena C; Cattaneo D; Scalzulli E; La Nasa G; Foà R; Breccia M
Int J Cardiol; 2019 Aug; 288():124-127. PubMed ID: 31029498
[TBL] [Abstract][Full Text] [Related]
11. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
12. [Cardiovascular management of patients with chronic myeloid leukemia from a multidisciplinary perspective, and proposing action protocol by consensus meeting].
García-Gutiérrez V; Jiménez-Velasco A; Gómez-Casares MT; Sánchez-Guijo F; López-Sendón JL; Steegmann Olmedillas JL
Med Clin (Barc); 2016 Jun; 146(12):561.e1-8. PubMed ID: 27107729
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.
Saglio G; le Coutre P; Cortes J; Mayer J; Rowlings P; Mahon FX; Kroog G; Gooden K; Subar M; Shah NP
Ann Hematol; 2017 Aug; 96(8):1303-1313. PubMed ID: 28534184
[TBL] [Abstract][Full Text] [Related]
14. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis.
Chai-Adisaksopha C; Lam W; Hillis C
Leuk Lymphoma; 2016; 57(6):1300-10. PubMed ID: 26373533
[TBL] [Abstract][Full Text] [Related]
15. [Management of cardiovascular complications in CML patients treated with tyrosine kinase inhibitors].
Matsumura I
Rinsho Ketsueki; 2018; 59(1):13-26. PubMed ID: 29415932
[TBL] [Abstract][Full Text] [Related]
16. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.
Nakazato T; Iriyama N; Tokuhira M; Ishikawa M; Sato E; Takaku T; Sugimoto KJ; Fujita H; Fujioka I; Kimura Y; Aisa Y; Iwanaga E; Asou N; Kizaki M; Hatta Y; Komatsu N; Kawaguchi T
Med Oncol; 2018 May; 35(7):99. PubMed ID: 29846829
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
[TBL] [Abstract][Full Text] [Related]
18. Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib.
Elnair R; Galal A
BMC Cancer; 2018 Nov; 18(1):1097. PubMed ID: 30419862
[TBL] [Abstract][Full Text] [Related]
19. Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database.
Fujioka I; Takaku T; Iriyama N; Tokuhira M; Kimura Y; Sato E; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Asou N; Kizaki M; Hatta Y; Komatsu N; Kawaguchi T
Ann Hematol; 2018 Nov; 97(11):2081-2088. PubMed ID: 29946911
[TBL] [Abstract][Full Text] [Related]
20. Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors.
Ren X; Qin Y; Huang X; Zuo L; Jiang Q
Ann Hematol; 2019 Jul; 98(7):1627-1640. PubMed ID: 31089794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]